Celgene Principal Scientist, DMPK in Cambridge, Massachusetts
Celgene is a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives. Our purpose as a company is to discover and develop therapies that will change the course of human health. We value our passion for patients, quest for innovation, spirit of independence and love of challenge. With a presence in more than 70 countries, and growing - we look for talented people to grow our business, advance our science and contribute to our unique culture.
The Principal Scientist, DMPK will provide scientific support to the discovery organization by providing knowledge and experience as an integral member of discovery project teams. The ideal candidate will serve as a DMPK representative in a number of Immunology/Immuno-oncology projects ranging from target ID, lead identification, and lead optimization to drug candidate nomination stages. The project representative is expected to provide a strong scientific leadership with a clear strategic direction to help navigate teams towards set milestones. He/She will closely work with Associate Director, DMPK to coordinate activities between the discovery teams and the internal DMPK-BA and pharmacology teams to ensure delivery of high quality data in a timely manner.
Responsibilities will include, but are not limited to, the following:
Participates in discovery teams to provide expertise and knowledge from the DMPK discipline. Works effectively in a multi-disciplinary team setting to facilitate medicinal chemistry SAR screening strategy with appropriate ADME/PK funnels and PK-PD-efficacy study design and execution Communicate effectively within and across groups to establish clear priorities and seek alignment on a work plan that meets discovery team needs Work closely with DMPK-BA internal team members to design decisional ADME experiments to influence the project in the right direction Work closely with pharmacology team to design and execute studies based on PK modeling and dose projections to enable PK-PD understanding of targets
Solid understanding of discovery ADME principles and an ability to integrate gained expertise into a rational discovery strategy
A strong foundation on met ID/biotransformation sciences and concepts
A broad understanding of SAR principles as it relates to in vitro ADME, DDI, and transporter assays
Proficiency in designing and interpreting preclinical PK studies with emphasis on IVIVCs with early human PK predictions Understanding of LC-MS/MS bioanalysis and concepts
Well versed in PK-PD-efficacy modeling principles to influence projects in the right direction
Excellent interpersonal and communications skills with a strong ability to influence various functions in a project team setting
Experience in PK and disposition modeling with WinNonlin preferred
General understanding of drug discovery & development processes including chemistry, pharmacology, pre-clinical formulations is an asset
Strong presence as well as sense of urgency and priorities as well as flexibility. The ability and strong desire to "make things happen".
Decisive as well as collaborative.
High level of honesty and integrity.
Excellent interpersonal skills with particular emphasis on communication & relationship building.
Motivated to be part of an organization that aims to make a difference through cutting edge research.
Passion for the pharmaceutical industry.
Celgene is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Celgene complies with all applicable national, state and local laws governing nondiscrimination in employment as well as employment eligibility verification requirements of the Immigration and Nationality Act. All applicants must have authorization to work for Celgene in the U.S.COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
“At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients.”
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.